trending Market Intelligence /marketintelligence/en/news-insights/trending/z6mv84DR0XHt2l91sOUF0w2 content esgSubNav
In This List

Alexion gains license to use Halozyme's drug-delivery technology

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Alexion gains license to use Halozyme's drug-delivery technology

Alexion Pharmaceuticals Inc. entered into a license agreement to use Halozyme Therapeutics Inc.'s Enhanze drug-delivery technology.

Under the terms of the agreement, Alexion may develop up to four targets, including the company's ALXN1210 formulation.

Alexion will pay Halozyme an initial $40 million. The agreement also includes an additional payment of $160 million for each target, subject to specified development, regulatory and sales-based milestones.

Halozyme will also receive royalties on sales of commercialized products.

The Enhanze technology enables a more rapid delivery of injectable medications through subcutaneous injection, which is just under the skin.